Research in earlier phases or small trials include evaluation of GLP-1s for indications such as cystic fibrosis-related diabetes, polycystic ovarian syndrome (PCOS), chronic obstructive pulmonary disease (COPD), Prader-Willi syndrome (PWS), asthma, substance or alcohol use disorder, and as add-on to insulin for type 1 diabetes
Heres how semaglutide injections can help in weight management: Wegovy mimics the GLP-1 hormone, reducing hunger and increasing fullness by activating brain receptors
By adhering to these recommendations, individuals can minimize the potential risks associated with combining phentermine and alcohol
Other digestive issues with weight loss drugs While constipation is a well-known side effect of GLP-1 receptor agonists, other gastrointestinal symptoms may include
FDA and PubMed Sources FDA